Is hemithyroidectomy a rational management for benign nodular goitre?

Basit Öğe Kaydı
dc.contributor.authorAttaallah, W.
dc.contributor.authorErel, S.
dc.contributor.authorCanturk, N. Z.
dc.contributor.authorErbil, Y.
dc.contributor.authorGorgulu, S.
dc.contributor.authorKulacoglu, H.
dc.contributor.authorKocdor, M. A.
dc.contributor.authorKebudi, A.
dc.contributor.authorOzbas, S.
dc.contributor.authorGulluoglu, B. M.
dc.date.accessioned2024-07-12T21:52:22Z
dc.date.available2024-07-12T21:52:22Z
dc.date.issued2015en_US
dc.departmentMaltepe Üniversitesien_US
dc.description.abstractBackground: The incidence and potential risk factors for the recurrence of benign nodular goitre after unilateral thyroidectomy are not clearly defined. The aim of this study was to assess the rate of progression of nodular goitre in the contralateral thyroid lobe and of hypothyroidism requiring replacement therapy after unilateral thyroid lobectomy for benign nodular goitre. Patients and Methods: Patients who underwent hemithyroidectomy for benign nodular goitre between 2000 and 2009 were included in the study. The primary outcome of this study was the reoperation rate for recurrent goitre, the rate of progression of nodular goitre and the rate of hypothyroidism requiring L-T4 replacement therapy. Clinical factors that have an effect on progression were further analysed. Results: 259 patients were included for study. Progression of the nodular goitre in the remnant lobe was observed in 32% (n = 83) of the patients. However, over time, only 2% of these 83 patients underwent contralateral hemithyroidectomy due to this progression. Fifty-six (22%) patients required L-thyroxin replacement due to persistent hypothyroidism after hemithyroidectomy. The factors shown to affect progression of nodular goitre were advanced age, preoperative hyperthyroidism, preoperative diagnosis of toxic nodular goitre and the presence of surgical indication for a toxic goitre causing hyperthyroidism and a definitive pathological diagnosis of nodular hyperplasia. Conclusion: There was a progression of the nodular goitre in the remnant lobe in about one-third of the patients who underwent hemithyroidectomy. However, only 2% of these patients underwent complementary contralateral hemithyroidectomy due to clinical progression in 31 months of follow-up.en_US
dc.identifier.endpage22en_US
dc.identifier.issn0300-2977
dc.identifier.issn1872-9061
dc.identifier.issue1en_US
dc.identifier.pmid26219937en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage17en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12415/8366
dc.identifier.volume73en_US
dc.identifier.wosWOS:000351540000004en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherVAN ZUIDEN COMMUNICATIONSen_US
dc.relation.ispartofNETHERLANDS JOURNAL OF MEDICINEen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzKY03088
dc.subjectBenign nodular goitreen_US
dc.subjecthemithyroidectomyen_US
dc.subjecthypothyroidismen_US
dc.subjectrecurrenceen_US
dc.titleIs hemithyroidectomy a rational management for benign nodular goitre?en_US
dc.typeArticle
dspace.entity.typePublication

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu